MD Pierre Amarenco

Risk of stroke and cardiovascular events after ischemic stroke or transient ischemic attack in patients with type 2 diabetes or metabolic syndrome: secondary analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial.

M. Hennerici, G. Samsa, L. Goldstein, 2011, Archives of neurology.